vs
Side-by-side financial comparison of OFG BANCORP (OFG) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $184.3M, roughly 1.6× OFG BANCORP). OFG BANCORP runs the higher net margin — 30.3% vs 12.8%, a 17.5% gap on every dollar of revenue. On growth, OFG BANCORP posted the faster year-over-year revenue change (0.9% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs 2.8%).
OFG Bancorp, founded in 1964, is the financial holding company for Oriental Bank, located in San Juan, Puerto Rico. OFG offers a wide range of retail and commercial banking, lending and wealth management products, services and technology, primarily in Puerto Rico and the U.S. Virgin Islands through its principal subsidiaries: Oriental Bank, Oriental Financial Services LLC, and Oriental Insurance LLC. Its headquarters are located at Oriental Center, 254 Muñoz Rivera Avenue, San Juan, PR 00918....
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
OFG vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $184.3M | $295.9M |
| Net Profit | $55.9M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | 25.7% | 18.4% |
| Net Margin | 30.3% | 12.8% |
| Revenue YoY | 0.9% | -6.4% |
| Net Profit YoY | 11.0% | 68.3% |
| EPS (diluted) | $1.27 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $184.3M | $295.9M | ||
| Q3 25 | $186.2M | — | ||
| Q2 25 | $182.4M | $317.0M | ||
| Q1 25 | $178.6M | $316.2M | ||
| Q4 24 | $182.7M | $297.0M | ||
| Q3 24 | $174.7M | $289.5M | ||
| Q2 24 | $179.8M | $306.1M | ||
| Q1 24 | $174.4M | $303.4M |
| Q4 25 | $55.9M | $38.0M | ||
| Q3 25 | $51.8M | — | ||
| Q2 25 | $51.8M | $-17.7M | ||
| Q1 25 | $45.6M | $22.6M | ||
| Q4 24 | $50.3M | $34.9M | ||
| Q3 24 | $47.0M | $33.6M | ||
| Q2 24 | $51.1M | $40.6M | ||
| Q1 24 | $49.7M | $49.1M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% |
| Q4 25 | 25.7% | 18.4% | ||
| Q3 25 | 33.0% | — | ||
| Q2 25 | 36.1% | -7.5% | ||
| Q1 25 | 33.3% | 12.2% | ||
| Q4 24 | 28.9% | 16.0% | ||
| Q3 24 | 35.4% | 13.8% | ||
| Q2 24 | 39.6% | 15.0% | ||
| Q1 24 | 38.9% | 22.1% |
| Q4 25 | 30.3% | 12.8% | ||
| Q3 25 | 27.8% | — | ||
| Q2 25 | 28.4% | -5.6% | ||
| Q1 25 | 25.5% | 7.1% | ||
| Q4 24 | 27.6% | 11.7% | ||
| Q3 24 | 26.9% | 11.6% | ||
| Q2 24 | 28.4% | 13.3% | ||
| Q1 24 | 28.5% | 16.2% |
| Q4 25 | $1.27 | $0.24 | ||
| Q3 25 | $1.16 | — | ||
| Q2 25 | $1.15 | $-0.11 | ||
| Q1 25 | $1.00 | $0.14 | ||
| Q4 24 | $1.10 | $0.22 | ||
| Q3 24 | $1.00 | $0.21 | ||
| Q2 24 | $1.08 | $0.26 | ||
| Q1 24 | $1.05 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.0B | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $1.4B | $2.0B |
| Total Assets | $12.5B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.0B | $172.9M | ||
| Q3 25 | $740.3M | — | ||
| Q2 25 | $851.8M | $162.2M | ||
| Q1 25 | $710.6M | $140.7M | ||
| Q4 24 | $591.1M | $177.5M | ||
| Q3 24 | $680.6M | $187.5M | ||
| Q2 24 | $740.4M | $152.9M | ||
| Q1 24 | $754.4M | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $1.4B | $2.0B | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.3B | $1.9B | ||
| Q1 25 | $1.3B | $2.0B | ||
| Q4 24 | $1.3B | $2.1B | ||
| Q3 24 | $1.3B | $2.1B | ||
| Q2 24 | $1.2B | $2.1B | ||
| Q1 24 | $1.2B | $2.0B |
| Q4 25 | $12.5B | $2.5B | ||
| Q3 25 | $12.2B | — | ||
| Q2 25 | $12.2B | $2.6B | ||
| Q1 25 | $11.7B | $2.6B | ||
| Q4 24 | $11.5B | $2.7B | ||
| Q3 24 | $11.5B | $2.7B | ||
| Q2 24 | $11.3B | $2.7B | ||
| Q1 24 | $11.2B | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $217.7M | — |
| Free Cash FlowOCF − Capex | $199.3M | — |
| FCF MarginFCF / Revenue | 108.1% | — |
| Capex IntensityCapex / Revenue | 10.0% | — |
| Cash ConversionOCF / Net Profit | 3.90× | — |
| TTM Free Cash FlowTrailing 4 quarters | $345.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $217.7M | — | ||
| Q3 25 | $39.5M | — | ||
| Q2 25 | $35.9M | $98.2M | ||
| Q1 25 | $83.1M | $41.1M | ||
| Q4 24 | $252.5M | $84.3M | ||
| Q3 24 | $58.1M | $63.9M | ||
| Q2 24 | $95.1M | $75.5M | ||
| Q1 24 | $61.0M | $81.0M |
| Q4 25 | $199.3M | — | ||
| Q3 25 | $35.5M | — | ||
| Q2 25 | $31.8M | $93.3M | ||
| Q1 25 | $78.7M | $31.0M | ||
| Q4 24 | $231.2M | $77.5M | ||
| Q3 24 | $51.8M | $54.7M | ||
| Q2 24 | $90.4M | $57.5M | ||
| Q1 24 | $54.8M | $64.5M |
| Q4 25 | 108.1% | — | ||
| Q3 25 | 19.1% | — | ||
| Q2 25 | 17.4% | 29.4% | ||
| Q1 25 | 44.1% | 9.8% | ||
| Q4 24 | 126.5% | 26.1% | ||
| Q3 24 | 29.6% | 18.9% | ||
| Q2 24 | 50.3% | 18.8% | ||
| Q1 24 | 31.4% | 21.3% |
| Q4 25 | 10.0% | — | ||
| Q3 25 | 2.1% | — | ||
| Q2 25 | 2.3% | 1.5% | ||
| Q1 25 | 2.4% | 3.2% | ||
| Q4 24 | 11.7% | 2.3% | ||
| Q3 24 | 3.6% | 3.2% | ||
| Q2 24 | 2.6% | 5.9% | ||
| Q1 24 | 3.5% | 5.4% |
| Q4 25 | 3.90× | — | ||
| Q3 25 | 0.76× | — | ||
| Q2 25 | 0.69× | — | ||
| Q1 25 | 1.82× | 1.82× | ||
| Q4 24 | 5.02× | 2.42× | ||
| Q3 24 | 1.24× | 1.90× | ||
| Q2 24 | 1.86× | 1.86× | ||
| Q1 24 | 1.23× | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OFG
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
